Florida Cancer Specialists & Research Institute (FCS) is pleased to welcome Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer. He will oversee all information technology operations and drive digital innovation company-wide.
Three Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.
Medical oncologists Lucio N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.
Lime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.
Hodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.
The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations.
FCS Top News Updates
FCS Signals Next Chapter of Growth With Planned Leadership Transition and Focus on Innovation
Florida Cancer Specialists & Research Institute Welcomes Ken Sturtz, MBA, MHA as Chief Information OfficerFlorida Cancer Specialists & Research Institute (FCS) is pleased to welcome Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer. He will oversee all information technology operations and drive digital innovation company-wide.
Florida Cancer Specialists & Research Institute Studies Featured at ASCO® Genitourinary Cancers SymposiumThree Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.
Lucio Gordan, MD, Ivor Percent, MD Co-Author Phase 3b/4 Renal Cell Carcinoma StudyMedical oncologists Lucio N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.
Nathan H. Walcker joins Lime Connect Global Board of DirectorsLime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.
FCS Spotlight: Meet Dr. Katy Phelan, Genetics Lab DirectorDr. Phelan identified the chromosome variant now known as Phelan-McDermid Syndrome
Florida Cancer Specialists & Research Institute Announces Senior Leadership AppointmentFCS announced the newest addition to its senior management team. Joshua Eaves joined FCS as Senior Vice President Corporate Development.
Understanding Hodgkin LymphomaHodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.
Advancing Therapies for Patients Through Clinical Research in Community Oncology PracticesThe survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly three decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations.